PriceTargets.com logo

Allakos - ALLK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.67
  • Forecasted Upside: 55.04%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.08 As of 12/17/2024 01:00 AM ET
▲ +0.01 (0.94%)

This chart shows the closing price for ALLK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allakos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALLK

Analyst Price Target is $1.67
▲ +55.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Allakos in the last 3 months. The average price target is $1.67, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 55.04% upside from the last price of $1.08.

This chart shows the closing price for ALLK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Allakos. This rating has held steady since December 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/26/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$3.00 ➝ $3.00
7/18/2024Jefferies Financial GroupLower TargetHold ➝ Hold$1.50 ➝ $1.00
6/26/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$3.00 ➝ $3.00
6/20/2024Cantor FitzgeraldReiterated RatingNeutral
1/17/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $3.00
1/17/2024BarclaysLower TargetUnderweight ➝ Underweight$1.50 ➝ $1.00
1/17/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00 ➝ $1.50
1/16/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
12/18/2023William BlairUpgradeMarket Perform ➝ Outperform
12/8/2023Jefferies Financial GroupReiterated RatingBuy$9.00 ➝ $6.00
11/28/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$10.00
11/14/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$11.00 ➝ $10.00
11/14/2023BarclaysLower TargetUnderweight ➝ Underweight$2.50 ➝ $1.50
9/27/2023JMP SecuritiesInitiated CoverageOutperform$11.00
5/11/2023Jefferies Financial GroupUpgradeHold ➝ Buy$6.00 ➝ $9.00
3/7/2023Cantor FitzgeraldReiterated RatingOverweight$7.00
3/7/2023Piper SandlerInitiated CoverageOverweight$22.00
3/7/2023Piper Sandler CompaniesInitiated CoverageOverweight$22.00
2/27/2023Cantor FitzgeraldReiterated RatingOverweight$7.00
1/27/2023Morgan StanleyBoost TargetEqual Weight$6.00 ➝ $8.00
9/12/2022Sumitomo Mitsui Financial GroupDowngradeNeutral ➝ Underperform
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
2/16/2022Leerink PartnersLower TargetMarket Perform$17.00 ➝ $13.00
12/28/2021HC WainwrightLower TargetBuy$230.00 ➝ $20.00
12/23/2021The Goldman Sachs GroupLower TargetNeutral$122.00 ➝ $60.00
12/22/2021Lifesci CapitalDowngradeOutperform ➝ Market Perform
12/22/2021Bank of AmericaDowngradeBuy ➝ Underperform
12/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
12/22/2021CowenDowngradeOutperform ➝ Market Perform
12/22/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$150.00 ➝ $17.00
12/22/2021William BlairDowngradeOutperform ➝ Market Perform
12/13/2021Bank of AmericaBoost TargetBuy$145.00 ➝ $155.00
11/10/2021Morgan StanleyLower TargetEqual Weight$88.00 ➝ $86.00
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
8/26/2021Morgan StanleyInitiated CoverageEqual Weight$88.00
7/15/2021CowenInitiated CoverageOutperform$76.53
5/18/2021HC WainwrightInitiated CoverageBuy$230.00
2/24/2021Cantor FitzgeraldInitiated CoverageOverweight$218.00
1/15/2021Bank of AmericaInitiated CoverageBuy$145.00
12/21/2020Leerink PartnersInitiated CoverageOutperform
10/22/2020Lifesci CapitalReiterated RatingOutperform
3/26/2020William BlairReiterated RatingBuy
2/27/2020BarclaysInitiated CoverageUnderweight$36.00
2/4/2020The Goldman Sachs GroupReiterated RatingNeutral$94.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Allakos logo
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $1.08
Low: $1.04
High: $1.11

50 Day Range

MA: $1.05
Low: $0.63
High: $1.50

52 Week Range

Now: $1.08
Low: $0.54
High: $3.41

Volume

252,770 shs

Average Volume

800,050 shs

Market Capitalization

$96.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Allakos?

The following equities research analysts have issued stock ratings on Allakos in the last year: Barclays PLC, Cantor Fitzgerald, Jefferies Financial Group Inc., JMP Securities, and William Blair.
View the latest analyst ratings for ALLK.

What is the current price target for Allakos?

0 Wall Street analysts have set twelve-month price targets for Allakos in the last year. Their average twelve-month price target is $1.67, suggesting a possible upside of 55.0%. JMP Securities has the highest price target set, predicting ALLK will reach $3.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $1.00 for Allakos in the next year.
View the latest price targets for ALLK.

What is the current consensus analyst rating for Allakos?

Allakos currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALLK, but not buy more shares or sell existing shares.
View the latest ratings for ALLK.

What other companies compete with Allakos?

Other companies that are similar to Allakos include Cryoport, Olema Pharmaceuticals, Procaps Group, Design Therapeutics and Neurogene. Learn More about companies similar to Allakos.

How do I contact Allakos' investor relations team?

Allakos' physical mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company's listed phone number is (650) 597-5002 and its investor relations email address is [email protected]. The official website for Allakos is www.allakos.com. Learn More about contacing Allakos investor relations.